This biotech stock rallying on cancer treatment data has more room to run, analysts say

Merus (MRUS) shares have surged approximately 40% in the past month, reaching an all-time high after promising Phase 2 data for its head and neck cancer treatment was presented at the American Society of Clinical Oncology's annual meeting; analysts project further upside, with some suggesting the stock could more than double based on potential Phase 3 success and expansion into colorectal cancer treatment, while also highlighting the possibility of an acquisition by a larger biopharmaceutical company and a potential boost to Merck's Keytruda sales.

Analysis

Merus N.V. (MRUS) has experienced a significant share price appreciation, surging approximately 40% in the past month to reach an all-time high, following the release of promising Phase 2 clinical trial data for its head and neck cancer treatment. This data, presented at the American Society of Clinical Oncology's annual meeting, has positioned Merus favorably against competitors like Bicara Therapeutics (BCAX), whose shares declined 24% over the same period, with analysts like William Blair's Matt Phipps deeming Merus' offering "first in class" and "best in class" particularly in combination with Merck's Keytruda. The strong analyst consensus, reflected by an LSEG poll showing all analysts with buy or strong buy ratings and an average price target suggesting 45% further upside, underscores the positive outlook. Guggenheim's Michael Schmidt projects that successful Phase 3 data, anticipated in 12 to 18 months, could more than double Merus' current valuation. Beyond head and neck cancer, the drug combination holds potential for colorectal cancer, with Phase 2 data expected in the second half of 2025, though current expectations for this indication are described by Schmidt as "very modest." The company is also viewed as a strong acquisition target by multiple analysts, including BMO's Evan Seigerman, due to its compelling clinical data addressing an unmet medical need. Furthermore, the success of Merus' treatment could positively impact Merck (MRK), as Leerink's Andrew Berens notes the combination significantly improves Keytruda's efficacy, potentially increasing patient response rates from approximately 20% to the high 60% range and extending treatment duration, thereby boosting Keytruda sales.

Key Decisions for Investors

• Given the robust Phase 2 data and strong analyst conviction, including an average price target suggesting 45% upside, investors could consider initiating or adding to positions in Merus (MRUS), while being prepared for a 12-18 month timeframe for potentially transformative Phase 3 data releases.
• Investors should closely track upcoming catalysts for Merus, notably the progression of its head and neck cancer treatment into Phase 3 trials and initial Phase 2 data for its colorectal cancer application expected in the second half of 2025, alongside monitoring for potential M&A activity given its stated appeal as an acquisition target.
• Holders of Merck (MRK) shares should recognize the ancillary benefit from Merus's pipeline success, as enhanced Keytruda efficacy, demonstrated by patient response rates increasing from circa 20% to the high 60% level and extended treatment duration, could positively contribute to Merck's revenue.